Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
